MDSpire - Summary
Feature

Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...

Share

Dr. Vivek Subbiah has been appointed the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, starting in spring 2026. He plans to enhance access to innovative cancer treatments via phase 1 trials and targeted therapies based on genetic markers. A leader in tumor-agnostic precision oncology, Dr. Subbiah has led over 150 trials and significantly contributed to clinical developments that adapt treatment strategies based on molecular profiling. His previous roles include leadership positions at Sarah Cannon Research Institute and MD Anderson Cancer Center. His appointment is expected to advance Stanford's efforts in early drug development and precision oncology while focusing on patient-centered care.

Original Source(s)

Stanford Names Leader for Drug Development and Precision Oncology

  • by The ASCO Post Staff

  • March 24, 2026

Related Content

Integrative Oncology Scholars Program

Applications are now being accepted for the 2026 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/vie...

In Celebration of a Decades-Long Journey of Discovery and Innovation

On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds th...

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

On March 5, 2026, the U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for the treatment of adult patients with relapsed or re...